Defecetive Drugs: adrugrecall.com
NEWSLETTER
Sign up for our newsletter
to receive breaking news about drugs to watch
Contact A Lawyer
Near You
Contact us today for a complimentary consultation with a qualified attorney near you.
New safety tests to begin on Celebrex
-October 18, 2004
Just days after Pfizer, Inc. warned doctors to be aware of possible links between its COX-2 arthritis and pain-relief drug Bextra and cardiovascular events, the company has announced it will begin new safety tests on its second COX-2 arthritis drug on the market, Celebrex. Both of Pfizer's arthritis drugs have been cast in negative light following the recall announcement of Vioxx, Merck & Co.'s COX-2 inhibitor drug.
Celebrex and Bextra are the only two remaining drugs currently on the market in the COX-2 class. Approved in 1998, Celebrex has been prescribed over 27 million times in the U.S. alone, according to Pfizer. The new safety tests are to begin early next year at major hospitals and universities around the world involving more than 4,000 patients. Pfizer has said in a statement that its new trials would involve people with heart problems that have a history of osteoarthritis as well. The study is set to last at least two years.
For more information on celebrex safety, please contact us.
